Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 7/20 | 0.41 |
| ▸ | CDK6 | Q00534 | 5/20 | 0.41 |
| ▸ | KHK | P50053 | 6/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22906920 | 0.88 | CHKA (0.38) | KHKALDH1A1 | |
| SCHEMBL27097204 | 0.85 | KHK (0.42) | KHKRPS6KA3 | |
| SCHEMBL27097206 | 0.83 | MAPT (0.39) | CDK4CDK6KHK | |
| SCHEMBL22906756 | 0.83 | KHK (0.46) | CDK4KHKALDH1A1 | |
| SCHEMBL27097283 | 0.82 | KHK (0.36) | CDK4CDK6KHKRPS6KA3ALDH1A1 | |
| SCHEMBL29773858 | 0.81 | ADRB2 (0.46) | ADRB2NCF1PLD1CDK4CDK6 | |
| SCHEMBL20133001 | 0.81 | ADRB2 (0.46) | ADRB2NCF1PLD1CDK4CDK6 | |
| SCHEMBL20120429 | 0.81 | ADRB2 (0.46) | ADRB2NCF1PLD1CDK4CDK6 | |
| SCHEMBL27097281 | 0.81 | KHK (0.33) | CDK4CDK6KHK | |
| SCHEMBL22906617 | 0.77 | TLR9 (0.42) | CDK4CDK6KHKRPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2021011913-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | ADRB2 4492/4885NCF1 3045/4885PLD1 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.